HPC Offered for PRESERVE Expansion

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Bone Marrow Transplant (BMT) Anemia Anemia, Aplastic Anemia, Hemolytic Anemia, Hemolytic, Congenital Anemia, Sickle Cell Bone Marrow Diseases Bone Marrow Failure Disorders Chronic Disease Congenital, Hereditary, and Neonatal Diseases and Abnormalities Disease Attributes Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Leukemia, Myeloid, Acute Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Myelodysplastic Syndromes Myeloproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms Precursor Cell Lymphoblastic Leukemia-Lymphoma

Age range

12 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Alabama, Birmingham, Birmingham, Alabama, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 12-80 may be eligible* to receive bone marrow for transplantation through the Ossium HOPE Program if:

Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks

Treatment and study plan

Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)

Other

The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.

Primary outcomes

Neutrophil engraftment

Time frame: 28 days
- To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)

Study contacts

Contact information is provided by the study sponsor or research team.

Preethi Prasad, Senior Director Clinical Operations

CONTACT

[email protected]

415-513-5535

Sponsors and collaborators

Lead sponsor

Ossium Health, Inc.

Industry

Registry information

Acronym: HOPE

Important dates

Study start: 2024
Primary completion: 2027
Study completion: 2029
First posted: Aug 28, 2025
Registry last updated: Aug 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting